GlassScriptPhysician profile
James G Beegan
NPI 1508831603
$10,638.88
in general payments reported to CMS, 2019-2025
66 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $709 · 2021: $1,207 · 2022: $1,858 · 2023: $1,762 · 2024: $2,411 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,102.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.94 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $688.02 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
| Amgen INC. | $658.57 | 2019-2023 | Aimovig |
| Novartis Pharmaceuticals Corporation | $548.75 | 2020-2025 | |
| Lilly USA, LLC | $526.70 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Sk Life Science, INC. | $479.98 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $410.51 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $401.59 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Neurocrine Biosciences, INC. | $358.01 | 2020-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $348.04 | 2019-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $345.15 | 2019-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $332.67 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $298.17 | 2019-2025 | Mavenclad |
| Allergan, INC. | $283.49 | 2019-2022 | |
| Pfizer INC. | $232.97 | 2022-2025 |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.